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Abstract
Paraneoplastic neurological syndromes (PNS) can be defined as remote effects of cancer that are
not caused by the tumor and its metastasis, or by infection, ischemia or metabolic disruptions. PNS
are rare, affecting less than 1/10,000 patients with cancer. Only the Lambert-Eaton myasthenic
syndrome is relatively frequent, occurring in about 1% of patients with small cell lung cancer. PNS
can affect any part of the central and peripheral nervous system, the neuromuscular junction, and
muscle. They can be isolated or occur in association. In most patients, the neurological disorder
develops before the cancer becomes clinically overt and the patient is referred to the neurologist
who has the charge of identifying a neurological disorder as paraneoplastic. PNS are usually severely
disabling. The most common PNS are Lambert-Eaton myasthenic syndrome (LEMS), subacute
cerebellar ataxia, limbic encephalitis (LE), opsoclonus-myoclonus (OM), retinopathies (cancer-
associated retinopathy (CAR) and melanoma-associated retinopathy (MAR), Stiff-Person syndrome
(SPS), chronic gastrointestinal pseudoobstruction (CGP), sensory neuronopathy (SSN),
encephalomyelitis (EM) and dermatomyositis. PNS are caused by autoimmune processes triggered
by the cancer and directed against antigens common to both the cancer and the nervous system,
designated as onconeural antigens. Due to their high specificity (> 90%), the best way to diagnose
a neurological disorder as paraneoplastic is to identify one of the well-characterized anti-
onconeural protein antibodies in the patient's serum. In addition, as these antibodies are associated
with a restricted range of cancers, they can guide the search for the underlying tumor at a stage
when it is frequently not clinically overt. This is a critical point as, to date, the best way to stabilize
PNS is to treat the cancer as soon as possible. Unfortunately, about one-third of patients do not
have detectable antibodies and 5% to 10% have an atypical antibody that is not well-characterized.
As PNS are believed to be immune-mediated, suppression of the immune response represents
another treatment approach.
Disease name
Paraneoplastic neurological syndromes (PNS)
Definition and diagnostic criteria
Paraneoplastic neurological syndromes (PNS) can be
defined as remote effects of cancer that are not caused by
the tumor and its metastasis, or by infection, ischemia or
metabolic disruptions [1,2]. In most patients, the neuro-
logical disorder develops before the cancer becomes clin-
ically overt and the patient is referred to neurologist who
has the charge of identifying a neurological disorder as
paraneoplastic.
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In the last two decades, the discovery that some PNS are
associated with antibodies directed against antigens
expressed by both the tumor and the nervous system
(onconeural antibodies), has suggested that these disor-
ders are immune-mediated. Even if numerous types of
paraneoplastic antibodies have been described [2-5], less
than 50% of patients with PNS harbor paraneoplastic
antibodies [4]. Thus, the absence of paraneoplastic anti-
bodies cannot rule out the diagnosis of PNS.
The presence or the absence of paraneoplastic antibodies
and the type of antibodies define different subtypes of
PNS. Recently, an international panel of neurologists
reviewed the existing criteria for diagnosis of PNS and rec-
ommended new diagnosis criteria for PNS [4]. The panel
suggested two levels of evidences necessary to define a
neurological syndrome as paraneoplastic: "definite" and
"possible". Each level can be reached combining a set of
criteria, which are based on the presence or absence of
cancer, and the definitions of "classical" syndrome and
"well characterized" onconeural antibody. PNS is "defi-
nite" when:
1. a classical neurological syndrome is observed (enceph-
alomyelitis, limbic encephalitis, subacute cerebellar
degeneration, sensory neuronopathy, opsoclonus-myo-
clonus, chronic gastrointestinal pseudoobstruction, Lam-
bert-Eaton myasthenic syndrome or dermatomyositis)
and cancer develops within five years of the diagnosis of
the neurological disorder;
2. a non-classical neurological syndrome is observed and
resolves or significantly improves after cancer treatment
without concomitant immunotherapy, provided that the
syndrome is not susceptible to spontaneous remission;
3. a non-classical neurological syndrome is observed with
onconeural antibodies and cancer develops within five
years of the diagnosis of the neurological disorder;
4. a neurological syndrome with well-characterized
onconeural antibodies (Ab) is observed (Hu-Ab, Yo-Ab,
CV2-Ab, Ri-Ab, Ma2-Ab or anphiphysin-Ab) and no can-
cer.
PNS is "possible" when:
1. a patient with classical neurological syndrome has no
onconeural antibodies and no cancer, but has a high risk
to have underlying tumor;
2. a patient presents with a neurological syndrome (classi-
cal or not) with partially characterized onconeural anti-
bodies, and no cancer.
3. a patient has a non-classical neurological syndrome
without onconeural antibodies, and cancer presents
within two years of diagnosis.
Epidemiology
PNS are rare diseases occurring in less than about 0.01%
of patients with cancer [2]. Only the Lambert-Eaton
myasthenic syndrome is relatively frequent, occurring in
about 1% of patients with small-cell lung cancer [6].
Clinical description
PNS may affect any level of the nervous system (central or
peripheral nervous system, including the neuromuscular
junction and muscle). The severity of most PNS is due to
the early and non-reversible destruction of neural struc-
tures by the inflammatory process [7,8]. PNS are rapidly
progressive, in many cases leaving the patients severely
debilitated within weeks to months. A subacute progres-
sive clinical course and a severe disability are highly sug-
gestive of PNS [4]. However, slow progression, relapses or
a benign course do not exclude the diagnosis.
Cerebro-spinal fluid (CSF) usually shows mild inflamma-
tory changes and oligoclonal bands [9].
Even if some neurological syndromes suggest a paraneo-
plastic origin, none of them are exclusively paraneoplastic
(Table 1) and non-paraneoplastic forms also exist [1].
Various antibodies have been reported in association with
PNS, defining different subtypes of PNS (Table 2). How-
ever, the description of PNS antibodies may also be con-
fusing, since a given antibody can be found in different
neurological syndromes and a given syndrome can be
associated with different antibodies.
The main neurological syndromes associated with a para-
neoplastic origin and the possible role of antibodies in
each case are briefly described bellow:
Limbic encephalitis (LE)
LE is characterized by the subacute onset of confusion
with marked reduction of the short-term memory. Sei-
zures are not uncommon and may antedate by months
the onset of cognitive deficit [10]. Other patients have a
more insidious onset with depression or hallucinations
that can lead to confusion the diagnosis with that of a psy-
chiatric illness. Among LE patients, 50% have small-cell
lung cancer (SCLC), 20% have a testicular tumor and 8%
have breast cancer [11]. Hu-Ab are present in up to 50%
of patients with LE and lung cancer [10,11]. A minority of
patients with LE and lung cancer may harbour CV2-Ab or
amphiphysin-Ab [12,13]. Ma2-Ab are present in the great
majority of patients with LE and testicular cancer. Unlike
patients with lung cancer, these patients usually present
with diencephalic and upper brainstem symptoms thatOrphanet Journal of Rare Diseases 2007, 2:22 http://www.OJRD.com/content/2/1/22
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Table 1: Main paraneoplastic neurological syndromes and associated antibodies
Paraneoplastic neurological syndromes Frequency of 
paraneoplastic origin
Main associated tumors Main frequent associated 
paraneoplastic antibodies
LEMS 60% SCLC VGCC-Ab*
Subacute cerebellar ataxia 50% Ovary, breast
SCLC
Hodgkin's disease
Others
Yo-Ab (PCA1-Ab**)
Hu-Ab (ANNA1-Ab**)
CV2-Ab (CRMP5-Ab**)
Tr-Ab
Ma-Ab (Ta-Ab**)
Opsomyoclonus 20% Neuroblastoma
Breast, lung
Hu-Ab (ANNA1-Ab**)
Ri-Ab (ANNA2-Ab**)
Sensory neuronopathy 20% SCLC Hu-Ab (ANNA1-Ab**)
CV2-Ab (CRMP5-Ab**)
Limbic encephalitis 20% SCLC
Testicular
SCLC
Hu-Ab (ANNA1-Ab**)
CV2-Ab (CRMP5-Ab**)
Ma2-Ab (Ta-Ab**)
Amphiphysin-Ab
Encephalomyelitis 10% SCLC Others Hu-Ab (ANNA1-Ab**)
CV2-Ab (CRMP5-Ab**)
Amphiphysin-Ab
Ma2-Ab (Ta-Ab**)
Retinopathy NA SCLC
Melanoma
Recoverin-Ab
CV2-Ab (CRMP5-Ab**)
Rod-bipolar-cell-Ab
Stiff-person syndrome 20% Breast Amphiphysin-Ab
Chronic gastrointestinal pseudoobstruction NA SCLC Hu-Ab (ANNA1-Ab**)
CV2-Ab (CRMP5-Ab**)
*VGCC-Ab are not really paraneoplastic antibodies because they are involved in LEMS but are not independent on the presence of a tumor
**Alternative nomenclature which can be found in the literature
Table 2: Main antibodies associated with Paraneoplastic neurological syndromes
Antibodies Main associated neurological syndromes Cancer
Hu-Ab (ANNA1-Ab**) Sensory neuronopathy
Encephalomyelitis
Chronic gastrointestinal pseudoobstruction
Cerebellar ataxia
Limbic encephalitis
SCLC
Yo-Ab (PCA1-Ab**) Subacute cerebellar ataxia Ovary, breast, uterus
CV2-Ab (CRMP5-Ab**) Cerebellar ataxia
Sensory-motor neuropathy
Uveitis, retinopathy
Encephalomyelitis
SCLC, thymoma
Ri-Ab (ANNA2-Ab**) Opsomyoclonus
Cerebellar ataxia
Breast, SCLC
Amphiphysin-Ab Stiff-person syndrome
Sensory neuronopathy
Encephalomyelitis
Breast, SCLC
Tr-Ab Cerebellar ataxia Hodgkin's disease
Ma2-Ab (Ta-Ab**) Limbic encephalitis Testicular
CAR-Ab Retinopathy Breast, SCLC
**Alternative nomenclature which can be found in the literatureOrphanet Journal of Rare Diseases 2007, 2:22 http://www.OJRD.com/content/2/1/22
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identify a characteristic syndrome in addition to limbic
encephalitis [14]. Recently, VGKC-Ab have been found in
some LE cases without associated cancer [15].
Subacute cerebellar ataxia
Paraneoplastic cerebellar ataxia (PCA) is characterized by
the rapid development of severe pancerebellar dysfunc-
tion due to an extensive loss of Purkinje neurons with rel-
ative preservation of other cerebellar neurons. Computed
tomography (CT) and magnetic resonance imaging (MRI)
studies are initially normal but demonstrate cerebellar
atrophy in the later stages of the disease.
Different autoantibodies have been reported in PCA
(Table 1). Yo-Ab are present in patients with PCA and
ovary, breast, or other gynecological malignancies
[16,17]. Tr-Ab are markers of patients with PCA and
Hodgkin's disease [18,19]. Unlike Yo-Ab, Tr-Ab usually
disappear after treatment of the tumor or, in a few
patients, are only found in the CSF [18]. Hu-Ab are
reported in 23% of patients with PCA and lung cancer
[20]. PCA and SCLC is also characteristic for patients with
CV2-Ab [12,21]. Zic4-Ab, Ma2-Ab and VGCC-Ab are
present in nearly 40% of patients with PCA and lung can-
cer (usually SCLC) [22-24]. About half of these patients
present a coincident Lambert-Eaton myasthenic syn-
drome [20].
Opsoclonus-myoclonus (OM)
Opsoclonus is defined by the presence of spontaneous,
arrhythmic and large amplitude conjugate saccades occur-
ring in all directions of gaze, without saccadic interval.
Opsoclonus is usually associated with myoclonus of the
limbs and trunk, and sometimes, with encephalopathy.
Paraneoplastic OM is observed in three clinical settings:
1) pediatric patients with neuroblastoma [25,26]; 2) adult
female patients with Ri-Ab, whose underlying tumor is
usually breast cancer [27,28], and 3) adult patients with-
out paraneoplastic antibodies whose tumor is almost
always SCLC [29,30]. There are individual case reports
associated with other tumors including carcinoma of the
uterus, Fallopian tube, breast, bladder, thyroid, thymus,
chondrosarcoma, and Hodgkin's disease. A few patients
with OM and SCLC or neuroblastoma may harbour Hu-
Ab [31].
Retinopathies
The paraneoplastic retinopathies include three well-char-
acterized syndromes [32]. Cancer-associated retinopathy
(CAR) is almost always associated with SCLC. Symptoms
usually present bilaterally and reflect the simultaneous
dysfunction of both cones and rods. Patients present with
photosensitivity, reduced visual acuity, decreased color
perception, ring scotomas, nyctalopia, and prolonged
dark adaptation [33]. Ophthalmoscopic examination typ-
ically shows attenuated arterioles, and electroretinogram
discloses flat or severely attenuated photic and scotopic
responses. Most of the patients with CAR have recoverin-
Ab, but other rare antibodies have also been described
[34,35].
Melanoma-associated retinopathy (MAR) usually occurs
after the diagnosis of malignant melanoma, often at the
stage of metastases. Patients with MAR usually have nearly
normal visual acuity and color vision but develop sudden
shimmering, flickering photopsias, night blindness, and
mild peripheral visual field loss [33]. Symptoms are
explained by dysfunction of rods, whereas cones are not
affected [36]. Typical findings in electroretinogram
include a markedly reduced or absent dark-adapted b-
wave, along with a slightly attenuated a-wave to scotopic
stimulus. Patients with MAR usually harbor rod-bipolar-
cell-Ab [37].
Uveitis, optic neuropathy or retinopathy are also observed
in some patients with CV2-Ab [12,38,39].
Chronic gastrointestinal pseudoobstruction (CGP)
Patients with CGP present with weight loss, persistent
constipation and abdominal distension due to damage of
the neurons of the enteric plexuses [40]. Some patients
may present with dysphagia, nausea and vomiting due to
esophageal dysmotility or gastroparesis, or more fre-
quently, with severe constipation. Radiologic studies
show small bowel, colonic or gastric dilatation. Esopha-
geal manometry may reveal spasms or achalasia. The most
commonly associated tumor and antibodies are SCLC and
Hu-Ab or CV2-Ab, respectively. Some patients with suba-
cute parasympathetic and sympathetic autonomic failure
and prominent gastrointestinal dysfunction may also
have antibodies directed against the neuronal autonomic
ganglion-type of acetylcholine receptors (nAchR antibod-
ies) [41]. In these cases, the main associated tumors are
thymoma and SCLC.
Sensory neuronopathy (SSN)
SSN is characterized by primary damage of the sensory
nerve cell body of the dorsal root ganglia. A paraneoplas-
tic origin is only one of the causes of SSN [42]. The most
common low associated tumor is SCLC [43]. The main
clinical complains at onset are pain and paresthesias with
asymmetric distribution that involves the arms rather
than the legs. Later, pain is replaced by numbness, limb
ataxia, and pseudoathetotic movements of the hands. The
neurologic examination shows abolition of the deep ten-
don reflexes and involvement of all modalities of sensa-
tion with clear predominance of the joint position.
Electrophysiologic studies show marked, but not
restricted, involvement of the sensory fibres [44]. Most ofOrphanet Journal of Rare Diseases 2007, 2:22 http://www.OJRD.com/content/2/1/22
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the patients with SSN have Hu-Ab, CV2-Ab or
amphiphysin-Ab [12,13,31,42].
Lambert-Eaton myasthenic syndrome (LEMS)
LEMS is an autoimmune disorder of the neuromuscular
junction characterized by muscle weakness and auto-
nomic dysfunction and, on electromyography, by low
compound muscle action potential after nerve stimula-
tion with decrement at low frequency stimulation (3 Hz)
of more than 10% and increment after high frequency
stimulation (more than 20 Hz or preferably maximal vol-
untary contraction) of more than 100% [45,46].
Almost 60% of patients with LEMS are paraneoplastic and
SCLC is the main associated cancer, detected mostly
within two years after the diagnosis of LEMS [45,46]. No
serological marker for the paraneoplastic etiology exists.
VGCC-Ab are present in nearly all patients with LEMS,
and these antibodies do not differ between the paraneo-
plastic and non-paraneoplastic form. In rare cases,
patients with paraneoplastic LEMS develop cerebellar
degeneration [47]. In contrast, some patients with parane-
oplastic cerebellar degeneration may have VGCC-Ab with-
out clinical signs or symptoms of myasthenic muscle
weakness [48].
Stiff-Person syndrome (SPS)
SPS is a rare neurological disorder characterized by stiff-
ness, more prominent in axial muscles, with co-contrac-
tion of agonist and antagonist muscle groups and painful
spasms precipitated by sensory stimuli. Electromyography
reveals the existence of continuous motor unit activity in
the affected muscles at rest. Detection of GAD-Ab in
almost 70% of patients suggests an autoimmune mecha-
nism.
A paraneoplastic variant of SPS has been described in
association with breast cancer in women harbouring
amphiphysin-Ab [49,50]. In these patients, the onset of
stiffness in upper limbs is suggestive of paraneoplastic eti-
ology. SPS has also been reported in association with
colon and lung cancer, Hodgkin's disease, and malignant
thymoma.
Encephalomyelitis (EM)
Paraneoplastic EM is characterized by involvement of dif-
ferent areas such as hippocampus, lower brainstem, spinal
cord or dorsal root ganglia in one and the same time [4].
The clinical picture reflects the variable anatomic involve-
ment and includes: LE, brainstem syndromes, autonomic
dysfunction, myelitis, CGP or SSN. In 75% of patients, the
underlying neoplasm is SCLC. SSN, LE and cerebellar
ataxia are the most common clinical syndromes. The
autonomic nervous system is affected in 30% of the
patients (orthostatic hypotension, urinary retention,
pupillary abnormalities [51], impotence and dry mouth).
Most of the patients present Hu-Ab, CV2-Ab or
amphiphysin-Ab [12,21,31,52].
Dermatomyositis
Dermatomyositis is an idiopathic inflammatory myopa-
thy with characteristic cutaneous manifestations includ-
ing heliotrope rash of the periorbital skin, erythematous
scaly plaques on dorsal hands with periungual tel-
angiectasia and photosensitive poikilodermatous erup-
tion. The myopathy is generally symmetrical and slowly
progressive during a period of weeks to months affecting
mainly the proximal muscles. A paraneoplastic origin is
suspected in 30% of patients [53,54] and the main associ-
ated cancer are ovarian, lung, pancreatic, stomach, and
colorectal cancers, and non-Hodgkin lymphoma. Many
autoantibodies such as nuclear antibodies or myositis-
associated antibodies have been recognized in dermato-
myositis, but none are linked to tumors. The treatment of
paraneoplastic dermatomyositis should be directed pri-
marily to the tumor, but immunosuppressive treatments
including corticosteroids, azathioprin and immunoglob-
ulins are also important.
Etiology
The discovery of onconeural antibodies has led to the
widely accepted nowadays hypothesis that PNS are
immune-mediated disorders. The autoimmune hypothe-
sis in PNS is also sustained by the inflammatory CSF find-
ings and T cell infiltration in the affected part of the
nervous system revealed by pathologic examination [55].
However, the role of onconeural antibodies in neurologi-
cal dysfunction is not clear.
PNS pathogenesis is currently related to an aberrant
expression in the tumor of an antigen that is normally
expressed only in the nervous system [56]. Even if the
antigens in the tumor are identical in structure to the neu-
ral antigens, they could be recognized as foreign, leading
to an immune attack directed against both the tumor and
the nervous system. However, only few onconeural anti-
bodies have been shown to play a direct role in the patho-
genesis of the neurological symptoms. The role of VGCC-
Ab has been demonstrated by the fact that the electro-
physiologic abnormalities characteristic for LEMS can be
reproduced when immunoglobulin G (IgG) from LEMS
patients is given to experimental animals [57]. Recoverin-
Ab are incorporated into rod photoreceptor cells and pro-
voke cell degeneration [34,35]. In contrast, the role of the
other paraneoplastic antibodies is not clear, probably
because the antigens are all intra-cellular. Hu-Ab, CV2-Ab,
Ri-Ab and Yo-Ab can be internalized into cell lines and
can interact with their antigens in vitro [58-60]. However,
it is not certain if these autoantibodies can cause cell lysis
in vivo as some of the results obtained in vitro are contro-Orphanet Journal of Rare Diseases 2007, 2:22 http://www.OJRD.com/content/2/1/22
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versial [61]. Moreover, immunization of experimental
animals with Hu or Yo antigens induces serum antibodies
but not neurological disease, and passive transfer of Yo-
Ab or Hu-Ab to experimental animals does not cause dis-
ease [62]. Thus, these paraneoplastic antibodies seem to
be only a marker of the autoimmunity and do not cause
the disease. Recently, it has been suggested that cellular
immune mechanisms play a critical role in the pathogen-
esis of PNS [63-65]. However, the results are not conclu-
sive [66].
Diagnosis and management
PNS may affect any part of the central and peripheral nerv-
ous system, the neuromuscular junction and muscle. They
can be isolated or occur in association. An important
point to keep in mind is that none of these disorders are
specifically paraneoplastic, as each disorder can also occur
in patients without cancer. The incidence of malignancy
in patients with potential PNS varies depending on the
disorder and ranging from 5 to 60% [67]. In almost 80%
of patients, the PNS antedates the diagnosis of cancer by
several months to several years. Most tumors are diag-
nosed within 4–6 months. It is accepted that the risk of
cancer development decreases significantly two years after
diagnosing PNS and becomes very low after four years. All
these data explain why it is often difficult to recognize a
given neurological disorder as paraneoplastic.
It has been shown that several PNS are associated with
onconeural antibodies. Unfortunately, almost 50% of
patients with true PNS do not have any of the well-charac-
terized onconeural antibodies [4]. In these patients, early
diagnosis of the tumor is frequently difficult, resulting in
a significant delay in tumor treatment [31]. To date, the
best way of stabilizing a PNS is probably to treat the
tumor as soon as possible. An early diagnosis of a neuro-
logical syndrome as PNS is thus crucial for the manage-
ment of patients. Detection of an onconeural antibody in
a patient suspected to have a PNS is, at present, the most
valuable diagnostic test [4].
Identification of the tumor
For patient with a neurological disorder that is highly sus-
pected to be paraneoplastic but for whom no cancer has
yet been identified, detection of the tumor is essential but
may be difficult since the tumors initially may be histolog-
ically small and localized [68]. If paraneoplastic antibod-
ies are present, they direct the tumor search to specific
organs. If a SCLC is suspected, the tumor is generally
detected by chest CT scan [69,70]. If a gynecological
tumor is suspected, careful breast and pelvic examination,
mammography and pelvic CT scan are recommended. If
no malignancy is revealed during initial workup, surgical
exploration and removal of pelvic organs may be war-
ranted, particularly in postmenopausal women [16]. The
use of whole-body positron emission tomography with
fluorodeoxyglucose (FDG-PET) should be reserved for
patients with paraneoplastic antibodies for whom con-
ventional imaging has failed to identify a tumor or when
lesions are difficult to biopsy [68,71]. In patients without
paraneoplastic antibodies, the sensitivity and specificity
of FDG-PET are less significant [72]. If a tumor which does
not fit the known tumor pattern associated with PNS is
identified, it should be checked for atypical expression of
the relevant antigen [31] and the possibility of a second
malignant disorder must be considered [73].
Treatment
The different subtypes of PNS are defined by the presence
or the absence of paraneoplastic antibodies and the type
of antibodies. Management and treatment should be tai-
lored to each subtype. For example, patients with SCLC
and PCA have different course of the neurological disor-
der, response to treatment, tumor prognosis and cause of
death, according to the presence or the absence of Hu-Ab
[20]. Patients with Ma2-Ab generally develop limbic and
brainstem encephalitis with testis tumors, but patients
with Ma2-Ab and additional antibodies directed against
other Ma proteins develop additional cerebellar symp-
toms and have tumors other than testis neoplasms [23].
The mean survival time for patients with SCLC and CV2-
Ab is 2.5 times longer than for patients with the same can-
cer, similar neurological symptoms and Hu-Ab [74]. All
these data suggest that the type of the immunological
stimulation against the tumor can determine a specific
course of the neurological disorder and give information
of whether the immunological response against the tumor
is more or less effective.
However, PNS rarely improves with immunomodulatory
treatment as in the majority of cases the neurological
symptoms are due to neuronal damage. The early and
non-reversible destruction of neural structures by the
inflammatory process accounts for both the severity of
most PNS and for the usual ineffectiveness of immu-
nomodulatory treatments [7,8]. The best chance of at least
stabilizing the syndrome is to induce a complete response
of the tumor [7]. Although immunotherapy is rarely effec-
tive, the use of intravenous immunoglobulins, steroids or
plasmapheresis is indicated because a few patients have
been reported to improve with these treatments [7,8,75].
Patients with Tr-Ab and Ma2-Ab and testicular cancer are
more likely to improve than those with other antibodies
[14,18].
Unresolved questions
To date, no studies have conclusively proved that parane-
oplastic antibodies are pathogenic; nevertheless, the para-
neoplastic antibodies are useful diagnostic markers that
can be used also to classify the different subtypes of PNS.Orphanet Journal of Rare Diseases 2007, 2:22 http://www.OJRD.com/content/2/1/22
Page 7 of 8
(page number not for citation purposes)
Some studies suggest that PNS with Yo-Ab, Ma-Ab or Hu-
Ab are probably autoimmune diseases directed against
Yo, Ma and Hu antigens respectively, and may be due to T
cell mediated destruction of neurons. However, further
studies are still required in order to characterize the mech-
anisms leading to neuronal death in PNS. Thus, the
hypothesis that PNS are immune-mediated remains to be
proved.
Conclusion
Finally, elucidation of the pathogenesis of PNS may have
important implications for understanding the neuronal
degeneration as well as tumor and brain immunology. As
PNS are rare, the diagnosis is difficult and frequently the
patient is misdiagnosed. Neurological symptoms usually
develop before the diagnosis of tumor that is in early and
limited stage and can be better treated by the current ther-
apies.
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